Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation

International Journal of Cancer

Volumn 132, Issue 7, 2013, Pages 1537-1546

  Gröschl, Benedikt ^a   Bettstetter, Marcus ^a   Giedl, Christian ^a   Woenckhaus, Matthias ^a   Edmonston, Tina ^b   Hofstädter, Ferdinand ^a   Dietmaier, Wolfgang ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Department of Anesthesiology   (United States)

Author keywords

colorectal cancer; DUSP4; microsatellite instability; MKP; MSI H

Indexed keywords

GENOMIC DNA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; PROTEIN DUSP4; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GENETICS; CCND1 GENE; CDC25A GENE; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN HCT116; CELL STRAIN SW480; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DUSP4 GENE; ENZYME REGULATION; ERG1 GENE; FOS GENE; GENE; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MSH2 GENE; ONCOGENE MYC; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COLON; COLORECTAL NEOPLASMS; DNA METHYLATION; DUAL-SPECIFICITY PHOSPHATASES; HUMANS; IMMUNOENZYME TECHNIQUES; MICROSATELLITE INSTABILITY; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECTUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84873094424     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27834     Document Type: Article

References (45)

1. Black EJ, Walker M, Clark W, MacLaren A, Gillespie DAF,. Cell transformation by v-Jun deactivates ERK MAP kinase signalling. Oncogene 2002; 21: 6540-8.
2. Misra-Press A, Rim CS, Yao H, Roberson MS, Stork PJ,. A novel mitogen-activated protein kinase phosphatase. Structure, expression, and regulation. J Biol Chem 1995; 270: 14587-96.
3. Chang L, Karin M,. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40.
4. Camps M, Nichols A, Arkinstall S,. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 2000; 14: 6-16.
5. Haneda M, Sugimoto T, Kikkawa R,. Mitogen-activated protein kinase phosphatase: a negative regulator of the mitogen-activated protein kinase cascade. Eur J Pharmacol 1999; 365: 1-7.
6. Cadalbert L, Sloss CM, Cameron P, Plevin R,. Conditional expression of MAP kinase phosphatase-2 protects against genotoxic stress-induced apoptosis by binding and selective dephosphorylation of nuclear activated c-jun N-terminal kinase. Cell Signal 2005; 17: 1254-64.
7. Dickinson RJ, Keyse SM,. Diverse physiological functions for dual-specificity MAP kinase phosphatases. J Cell Sci 2006; 119: 4607-15.
8. Farooq A, Zhou M,. Structure and regulation of MAPK phosphatases. Cell Signal 2004; 16: 769-79.
9. Brondello JM, Brunet A, Pouysségur J, McKenzie FR,. The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J Biol Chem 1997; 272: 1368-76.
10. Chen P, Hutter D, Yang X, Gorospe M, Davis RJ, Liu Y,. Discordance between the binding affinity of mitogen-activated protein kinase subfamily members for MAP kinase phosphatase-2 and their ability to activate the phosphatase catalytically. J Biol Chem 2001; 276: 29440-9.
11. Owens DM, Keyse SM,. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007; 26: 3203-13.
12. Cadalbert LC, Sloss CM, Cunningham MR, Al-Mutairi M, McIntire A, Shipley J, Plevin R,. Differential regulation of MAP kinase activation by a novel splice variant of human MAP kinase phosphatase-2. Cell Signal 2010; 22: 357-65.
13. Keyse SM,. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 2008; 27: 253-61.
14. Teutschbein J, Haydn JM, Samans B, Krause M, Eilers M, Schartl M, Meierjohann S,. Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins. BMC Cancer 2010; 10: 386.
15. Sieben NLG, Oosting J, Flanagan AM, Prat J, Roemen GMJM, Kolkman-Uljee SM, van Eijk R, Cornelisse CJ, Fleuren GJ, van Engeland M,. Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J Clin Oncol 2005; 23: 7257-64.
16. Cornell TT, Rodenhouse P, Cai Q, Sun L, Shanley TP,. Mitogen-activated protein kinase phosphatase 2 regulates the inflammatory response in sepsis. Infect Immun 2010; 78: 2868-76.
17. Wang H, Cheng Z, Malbon CC,. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 2003; 191: 229-37.
18. Armes JE, Hammet F, Silva M, de Ciciulla J, Ramus SJ, Soo W, Mahoney A, Yarovaya N, Henderson MA, Gish K, Hutchins A, Price GR, Venter DJ,. Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene 2004; 23: 5697-702.
19. Waha A, Felsberg J, Hartmann W, dem Knesebeck A, von Mikeska T, Joos S, Wolter M, Koch A, Yan PS, Endl E, Wiestler OD, Reifenberger G, et al. Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res 2010; 70: 1689-99.
20. Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman JM, Major J, et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 2009; 28: 2773-83.
21. Britson JS, Barton F, Balko JM, Black EP,. Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signaling. Biochem Biophys Res Commun 2009; 390: 849-54.
22. Gaedcke J, Grade M, Jung K, Camps J, Jo P, Emons G, Gehoff A, Sax U, Schirmer M, Becker H, Beissbarth T, Ried T, Ghadimi BM,. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes, chromosomes & cancer 2010; 49: 1024-34.
23. Shen WH, Wang J, Wu J, Zhurkin VB, Yin Y,. Mitogen-activated protein kinase phosphatase 2: a novel transcription target of p53 in apoptosis. Cancer Res 2006; 66: 6033-9.
24. Yip-Schneider MT, Lin A, Marshall MS,. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochem Biophys Res Commun 2001; 280: 992-7.
25. Dietmaier W, Bettstetter M, Wild PJ, Woenckhaus M, Rümmele P, Hartmann A, Dechant S, Blaszyk H, Pauer A, Klinkhammer-Schalke M, Hofstädter F,. Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer. Int J Cancer 2006; 118: 2247-54.
26. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43.
27. Bettstetter M, Dechant S, Ruemmele P, Vogel C, Kurz K, Morak M, Keller G, Holinski-Feder E, Hofstaedter F, Dietmaier W,. MethyQESD, a robust and fast method for quantitative methylation analyses in HNPCC diagnostics using formalin-fixed and paraffin-embedded tissue samples. Lab Invest 2008; 88: 1367-75.
28. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS,. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005; 7: 413-21.
29. Kriegl L, Neumann J, Vieth M, Greten FR, Reu S, Jung A, Kirchner T,. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol 2011; 24: 1015-22.
30. Peng D, Zhou J, Wu GS,. Post-translational regulation of mitogen-activated protein kinase phosphatase-2 (MKP-2) by ERK. Cell Cycle 2010; 9: 4650-5.
31. Zhang T, Wolfe MW, Roberson MS,. An early growth response protein (Egr) 1 cis-element is required for gonadotropin-releasing hormone-induced mitogen-activated protein kinase phosphatase 2 gene expression. J Biol Chem 2001; 276: 45604-13.
32. Wang J, Shen WH, Jin YJ, Brandt-Rauf PW, Yin Y,. A molecular link between E2F-1 and the MAPK cascade. J Biol Chem 2007; 282: 18521-31.
33. Wang H, Lu Y, Huang W, Papoutsakis ET, Fuhrken P, Eklund EA,. HoxA10 activates transcription of the gene encoding mitogen-activated protein kinase phosphatase 2 (Mkp2) in myeloid cells. J Biol Chem 2007; 282: 16164-76.
34. Nunes-Xavier C, Romá-Mateo C, Ríos P, Tárrega C, Cejudo-Marín R, Tabernero L, Pulido R,. Dual-specificity MAP kinase phosphatases as targets of cancer treatment. Anticancer Agents Med Chem 2011; 11: 109-32.
35. Cagnol S, Rivard N,. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. Oncogene 2012 Mar 19. doi: 10.1038/onc.2012.88. [Epub ahead of print].
36. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP,. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-6.
37. Ciccarelli C, Marampon F, Scoglio A, Mauro A, Giacinti C, Cesaris P, de Zani BM,. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells. Mol Cancer 2005; 4: 41.
38. Lawan A, Al-Harthi S, Cadalbert L, McCluskey AG, Shweash M, Grassia G, Grant A, Boyd M, Currie S, Plevin R,. Deletion of the dual specific phosphatase-4 (DUSP-4) gene reveals an essential non-redundant role for MAP kinase phosphatase-2 (MKP-2) in proliferation and cell survival. J Biol Chem 2011; 286: 12933-43.
39. Hasegawa T, Enomoto A, Kato T, Kawai K, Miyamoto R, Jijiwa M, Ichihara M, Ishida M, Asai N, Murakumo Y, Ohara K, Niwa Y, et al. Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice. Oncogene 2008; 27: 5684-95.
40. Michael-Robinson JM, Reid LE, Purdie DM, Biemer-Hüttmann AE, Walsh MD, Pandeya N, Simms LA, Young JP, Leggett BA, Jass JR, Radford-Smith GL,. Proliferation, apoptosis, and survival in high-level microsatellite instability sporadic colorectal cancer. Clin Cancer Res 2001; 7: 2347-56.
41. Boland CR, Goel A,. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-2087.e3.
42. Zaanan A, Meunier K, Sangar F, Fléjou J, Praz F. Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications. Cell. Oncol. (Dordrecht) 2011; 34: 155-76.
43. Taupin D, Podolsky DK,. Mitogen-activated protein kinase activation regulates intestinal epithelial differentiation. Gastroenterology 1999; 116: 1072-80.
44. Fang JY, Richardson BC,. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005; 6: 322-7.
45. Vlahopoulos S, Zoumpourlis VC,. JNK: a key modulator of intracellular signaling. Biochem Mosc 2004; 69: 844-54.